Zobrazeno 1 - 4
of 4
pro vyhledávání: '"59"'
Autor:
Marylin Torrentino-Madamet, Louis Collet, Nicolas Benoit, Didier Menard, Jean François Lepere, Bruno Pradines, Rémy Amalvict
Publikováno v:
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, 2015, 59 (12), pp.7878-7881. ⟨10.1128/AAC.01251-15⟩
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2015, 59 (12), pp.7878-7881. ⟨10.1128/AAC.01251-15⟩
Antimicrobial Agents and Chemotherapy, 2015, 59 (12), pp.7878-7881. ⟨10.1128/AAC.01251-15⟩
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2015, 59 (12), pp.7878-7881. ⟨10.1128/AAC.01251-15⟩
Plasmodium falciparum isolates were collected from 29 malaria patients treated with artemether-lumefantrine in Mayotte in 2013 and 2014. Twenty-four cases (83%) consisted of imported malaria. Seventeen percent of the isolates presented mutations in o
Autor:
Timothy M. E. Davis, Harin Karunajeewa, Peter A. Zimmerman, Ivo Mueller, Rina P. M. Wong, Peter Siba
Publikováno v:
Antimicrobial Agents and Chemotherapy. 55:798-805
Surveillance for Plasmodium falciparum drug resistance mutations is becoming an established tool for assessing antimalarial treatment effectiveness. We used an extended version of a high-throughput post-PCR multiplexed ligase detection reaction fluor
Publikováno v:
Antimicrobial Agents and Chemotherapy. 48:2924-2929
The resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine (SP) is an emerging public health threat. Resistance to these drugs is associated with point mutations in the genes encoding dihydropteroate synthase (DHPS) and dihydrofolate reduct
Autor:
Yoshiyasu Karino, Tadasu Shin-I, Kohsaku Sakaguchi, Masashi Mizokami, Etsuro Orito, Yasuhito Tanaka, Motokazu Mukaide, Manami Inoue, Gotaro Yamada, Ching-Lung Lai, Michio Sata, Man-Fung Yuen, Sumbella Baqai, Fuat Kurbanov, Osamu Yokosuka
Publikováno v:
Antimicrobial agents and chemotherapy. 54(2)
The mechanism by which entecavir resistance (ETVr) substitutions of hepatitis B virus (HBV) can induce breakthrough (BT) during ETV therapy is largely unknown. We conducted a cross-sectional study of 49 lamivudine (LVD)-refractory patients and 59 na